title: [Long-term control of sacral metastasis from rectal cancer with S-1 + radiation treatment (RT) and mFOLFOX6 combination therapy--a case report].
abstract: Combined chemotherapy including 5-FU plus radiation treatment resulted in a synergistic effect has been reported. S-1 enhances a radiation response of colon cancer cell line xenografts. Also the effectiveness of S-1 + radiation therapy has been reported. A 66-year-old man underwent a low anterior resection for lower rectal cancer. Adjuvant chemotherapy was not performed due to Stage II rectal cancer. Twenty months after the operation, solitary sacral bone metastasis was found during the postoperative work-up. S-1 (120 mg/day) combined with radiotherapy was performed on days 1-14 and 21-35. Radiation (3 Gy) was administered a total of 45 Gy on days 1-5, 7-12 and 35-40. Moreover, the reduction was judged as complete response after 11 courses of mFOLFOX 6. There has been no sign of recurrence for 44 months. It suggested that local control therapy (S-1 + radiation) plus systemic chemotherapy (mFOLFOX6) was one of the promising effective therapies for single sacral bone metastasis of rectal cancer.
authors.affiliation: Dept. of Surgery, Toyonaka Municipal Hospital.
authors.forename: Taishi
authors.initials: T
authors.lastname: Hata
authors.forename: Siki
authors.initials: S
authors.lastname: Fujino
authors.forename: Takehiro
authors.initials: T
authors.lastname: Yanagawa
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Kitahara
authors.forename: Kouji
authors.initials: K
authors.lastname: Munakata
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Watanabe
authors.forename: Kaori
authors.initials: K
authors.lastname: Takamoto
authors.forename: Masakazu
authors.initials: M
authors.lastname: Miyake
authors.forename: Kenshu
authors.initials: K
authors.lastname: Kawanishi
authors.forename: Junzo
authors.initials: J
authors.lastname: Shimizu
authors.forename: Kimimasa
authors.initials: K
authors.lastname: Ikeda
authors.forename: Junya
authors.initials: J
authors.lastname: Fujita
authors.forename: Takashi
authors.initials: T
authors.lastname: Iwazawa
authors.forename: Kenzo
authors.initials: K
authors.lastname: Akagi
authors.forename: Keizou
authors.initials: K
authors.lastname: Douno
authors.forename: Masashi
authors.initials: M
authors.lastname: Kitada
authors.forename: Takashi
authors.initials: T
authors.lastname: Shimano
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000556:secondary* / Q000628:therapy*; D003131:Combined Modality Therapy; D004338:Drug Combinations; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D010094:Oxonic Acid / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D012004:Rectal Neoplasms / Q000473:pathology* / Q000601:surgery; D012447:Sacrum; D005641:Tegafur / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; D009944:Organoplatinum Compounds; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002955:Leucovorin; D005472:Fluorouracil